Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2022-03-14 Transaction in Own Shar…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
国浩律师（深圳）事务所关于控股股东、实际控制人增持公司股份的法律意见书
Transaction in Own Shares Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the increase in shareholding by the controlling shareholder and actual controller of a company. It discusses the legal qualifications of the shareholder, details of the share increase, compliance with relevant laws and regulations, and confirms that the share increase does not require a mandatory tender offer. The document is focused on legal compliance and shareholding changes rather than financial results, management changes, or general regulatory announcements. It is not an annual report, earnings release, or management report. It is a legal opinion related to a transaction in own shares (share repurchase or issuance) by a controlling shareholder. Therefore, the most appropriate classification is Transaction in Own Shares (POS). The document length is 4621 characters, which is sufficient to be the actual legal opinion document, not just an announcement or certification, so it is not RNS or RPA.
2022-03-14 Chinese
关于控股股东、实际控制人增持公司股份计划实施完成的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the completion of a share increase plan by the controlling shareholder and actual controller of the company. It details the number of shares increased, the percentage of total shares, the purpose of the increase, and legal compliance. There is no financial report, earnings data, or management discussion. The document is a formal disclosure of a significant shareholding transaction by a major shareholder, specifically the controlling shareholder increasing their stake. This fits the definition of a Major Shareholding Notification (MRQ). The document length is 2675 characters, which is relatively short and focused on the shareholding change, not a full report or announcement of a report publication. Therefore, the correct classification is MRQ with high confidence.
2022-03-14 Chinese
关于控股子公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a subsidiary obtaining a medical device registration certificate from the National Medical Products Administration. It describes the product details, impact on the company, and risk warnings. There is no financial data, no mention of financial results, no voting results, no management changes, no legal proceedings, no capital changes, and no report publication. The document is a regulatory announcement about a product approval, which fits best under Regulatory Filings (RNS) as it does not fit other specific categories.
2022-03-07 Chinese
关于控股子公司取得医疗器械注册证的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company about its controlling subsidiary obtaining a medical device registration certificate. It details the product name, registration number, validity period, clinical use, and the impact on the company. There is no financial data, no mention of financial results, no regulatory filings or certifications, and no reference to shareholder meetings or votes. The document is a regulatory announcement about a product approval, which does not fit into financial report categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is a regulatory announcement about a business development. Given the content and length (972 characters), it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other categories.
2022-02-28 Chinese
关于向公司2022年股票期权激励计划激励对象首次授予股票期权的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the company's 2022 stock option incentive plan, specifically about the initial grant of stock options to incentive recipients. It includes information on the authorization date, exercise price, number of options granted, eligibility criteria, performance assessment requirements, and legal opinions. The document is not a financial report or earnings release but rather a formal announcement of a capital-related event involving stock options and equity incentives. This fits the category of Capital/Financing Update (CAP), as it relates to changes in the company's capital structure through stock option grants. The document length is substantial and contains detailed information about the stock option plan implementation, approvals, and legal compliance, confirming it is not a mere announcement of a report but a substantive update on financing activities.
2022-02-15 Chinese
关于调整2022年股票期权激励计划相关事项的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding adjustments to the 2022 stock option incentive plan of the company. It details board and supervisory meetings, approvals, legal opinions, and changes in the number of incentive recipients and stock options granted. It does not contain financial statements or detailed financial performance data. The document is primarily about management decisions related to stock option plans, which is a governance and management-related announcement. It is not a full annual or interim report, nor an earnings release or capital update. It is also not a proxy solicitation or voting result announcement. Given the content focuses on management decisions and board approvals related to stock option incentives, the best fitting category is Board/Management Information (MANG). The document length is short and it is a formal announcement of management decisions rather than a report or presentation.
2022-02-15 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.